Nektar Therapeutics (NKTR)

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 20, 2026 1:58 AM
PR Newswire (US)

LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302746762.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 13, 2026 2:40 AM
PR Newswire (US)

LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302740073.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRApril 6, 2026 4:14 AM
PR Newswire (US)

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025
DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302734449.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 23, 2026 2:10 AM
PR Newswire (US)

LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302721721.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 20, 2026 4:06 AM
PR Newswire (US)

LOS ANGELES, March 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. SchwartzDJS Law Group274 White Plains Road, Suite 1 Eastchester, NY 10709Phone: 914-206-9742Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302719512.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTRMarch 16, 2026 3:09 AM
PR Newswire (US)

LOS ANGELES, March 16, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.CLASS PERIOD: February 26, 2025 to December 15, 2025DEADLINE: May 5, 2026CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. Based on these facts, Nektar's public statements were false and materially misleading throughout the class period.If you are a shareholder who suffered a loss, contact us to participate.WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.Join the case to recover your losses.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com



View original content:https://www.prnewswire.com/news-releases/nektar-therapeutics-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--nktr-302714246.htmlSOURCE DJS Law Group LLP

Original: Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

300 mil

doesnt anyone care about the huge 200 mil shares they are selling???killing shareholders???

Nektar gains after durable efficacy shown in atopic dermatitis studyFebruary 10, 2026 10:46 AM
IH Market News
Shares of Nektar Therapeutics (NASDAQ:NKTR) moved higher on Tuesday after the company released encouraging long-term maintenance results from its REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The stock was up about 3% in morning trading.The clinical-stage biotech said patients receiving rezpegaldesleukin, a regulatory T-cell–targeting biologic, sustained strong clinical responses through week 52 under both monthly and quarterly dosing schedules.Trial data showed that 71% of patients on a 24 µg/kg monthly regimen and 83% on quarterly dosing maintained EASI-75 responses. For vIGA-AD 0/1 outcomes, 85% of monthly-dosed patients and 63% of those on quarterly dosing sustained their responses. The company also reported up to a fivefold increase in EASI-100 responses, signaling complete skin clearance in a subset of patients.REZOLVE-AD is a global Phase 2b study that enrolled 393 patients. After a 16-week induction phase, participants who achieved at least a 50% improvement in EASI scores were re-randomized to receive maintenance therapy either monthly or quarterly for a further 36 weeks.Nektar said the treatment’s safety profile remained consistent with earlier findings, with no new safety signals observed during the maintenance phase. Discontinuations due to adverse events were limited to 3.5% across all patients.“These data validate the novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator,” the company said, adding that the durability of responses supports moving into a pivotal Phase 3 program evaluating both dosing schedules.Nektar plans to submit a Biologics License Application for rezpegaldesleukin in 2029.Nektar Therapeutics stock price

Original: Nektar gains after durable efficacy shown in atopic dermatitis study

An analysis based on recently released clinical data.

https://www.linkedin.com/posts/clinrm-llc_rezolve-ad-my-perspective-on-rezpegaldesleukin-activity-7394464715348799489-ABEE?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAm29xsBQ8kMRFuhQRFYyVV3mnMlQ-_jT1M

I see the market poured more salt in your wound!! Lol 😂 Cowardly lion 🦁

You only lose if the stock price goes down!! A RS does not mean you automatically lose. Your shares have the same value!! Just admit you didn't believe in yourself!! The story of your life!!

THEY JUST DID A RS NITWITT ON THE 9TH...WHY WOULD I HOLD ALL THIS TIME TO LOSE ALL MY SHARES....U HAVE NO CLUE...NEXT!!!!

Fake trade just imagine if you believed in yourself and loaded this ticker when you posted?? That's a boss but no....I get up every morning at 5Am!! LOL 😂 Loser!!

NOBODY CAN PREDICT GAPS...PRETEND TRADERS LIKE MAGGOTZMONEY IS A TICKER CALLER NOT ...A TRADER...HE OWNS NOTHING BUT MDCE....HES LIKE YOU...LOST HIS MONEY IN THE OTC AND PRETENDS TO BE A BIG BOARD TRADER NOW....MAGGOTS EVERYWHERE!!!

NKTR............................................weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee

Guess you missed this one sleeping late!! Lol 😂 😂😂

$NKTR: BOOooommmmmmmmm............... up 150% in PreMarket

Now $24.............. wow.


Got some real flyers going off already.


GO $NKTR

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR.......................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR.................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR...................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR....................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

Any news? why the jump? anybody...

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR....................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR...READY TO BREAK OUT!

NKTR............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR.........................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 week high

NKTR under $2

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 hi

NKTR here we go. Every time I go higher with my bench press this stocks follows

NKTR setting up here

NKTR...MASSIVE VOLUME

NKTR...PUSHING TO THE TOP OF THE WEEKLY CLOUD....WILL SHE BREAK FOR BLUE SKY!!!

NKTR........................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR new 52 hi

NKTR new 52 hi

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

NKTR.......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

NKTR 10Q March 4

NKTR new 52 week low

NKTR new 52 week low